Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Silencing of PKG1 expression enhances the efficacy of vemurafenib against melanoma cell].

Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology - 8 Apr 2017

Liu Rong, Wan Xin, Wang Xi, Li Fan-Lu, Jing Jia-Ni, Cui Xiang-Li

Abstract excerpt

OBJECTIVE: To explore whether targeting phosphoglycerate kinase 1 (PGK1) can enhance the sensitivity of BRAFV600E mutation melanoma cells to vemurafenib. METHODS: The methods of cell biology, molecular biology and pharmacology(MTT assay, Western blot, FCM, Colongenic assay) were used in this study. RESULTS: ① Silencing of PGK1 expression increased the efficacy of vemurafenib in melanoma cells, as evidenced by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Gene Silencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Melanoma

Share to Phosphoglycerate Kinase

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 29926631
DOI: 10.12047/j.cjap.5559.2017.071

Genes

PGK1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Silencing of PKG1 expression enhances the efficacy of vemurafenib against melanoma cell].PMID 29926631Read ↗

[Progress of anti-tumor study based on BRAF].Semantic proximity Read ↗

Overcoming Chemoresistance to Vemurafenib in Melanoma via Targeted Inhibition of PCK1 Using 3-mercaptopropionic AcidSemantic proximity Read ↗

Specifically targeting ERK1 or ERK2 kills Melanoma cellsSemantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib.Semantic proximity Read ↗

[Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].Semantic proximity Read ↗

Genetic silencing of AKT induces melanoma cell deathSemantic proximity Read ↗

Polo-like kinase 1 is a potential therapeutic target in human melanoma.Semantic proximity Read ↗

miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanomaSemantic proximity Read ↗

Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma.Semantic proximity Read ↗

The Downregulation of EIF3a Contributes to Vemurafenib Resistance in Melanoma By Activating ERK Via PPP2R1BSemantic proximity Read ↗

Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.